Abstract Funding Acknowledgements Type of funding sources: None. Introduction Recent
European Society of Cardiology (ESC) guidelines on the treatment of dyslipidemia …

From a historical point of view, adequate treatment for dyslipidemia has been discussed and
changed for long. There are recently four common broadly used agents, which are I) statins …

Background It is known that less than half of patients with coronary heart disease reaches
the target of LDL cholesterol (LDL-C)< 100 mg/dl. According to the latest international …

Management of hyperlipidaemia in patients with ischaemic heart disease is suboptimal
despite the proven benefit of statin therapy. Significant improvement in management has …

Background: Five multicentre, cross-sectional Centralized Pan-regional Surveys on the
Undertreatment of Hypercholesterolemia (CEPHEUS) were conducted in 29 countries …

BACKGROUND: Previous retrospective surveys have shown that lipid management goals
are well achieved in patients with dyslipidemia at relatively low risk for atherosclerotic …

Dyslipidemia is a modifiable risk factor for cardiovascular diseases. Recommendations are
based on achieving LDL-C target levels, but it is essential to assess the benefits of …

Background and aims One of the objectives of the ESC-EORP EUROASPIRE V survey is to
determine how well European guidelines on the management of dyslipidaemias are …

Abstract Purpose of Review Current guidelines on the management of patients with
dyslipidemias recommend specific risk-dependent low-density lipoprotein cholesterol (LDL …

Lowering of low-density lipoprotein (LDL) cholesterol is a fundamental step in the
comprehensive management of patients at high risk for cardiovascular events. The …